NasdaqGS - Delayed Quote USD

ImmunityBio, Inc. (IBRX)

7.35 +2.24 (+43.84%)
At close: April 26 at 4:00 PM EDT
7.59 +0.24 (+3.27%)
After hours: April 26 at 7:59 PM EDT
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for IBRX

Recent News: IBRX

View More
ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

ImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer
Business Wire 2 days ago
ImmunityBio's bladder cancer therapy wins FDA approval

ImmunityBio's bladder cancer therapy wins FDA approval
Yahoo Finance Video 4 days ago
ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

ImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
Business Wire 5 days ago
NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy

NIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral Therapy
Business Wire last month
N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study
Business Wire last month
ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

ImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial
Business Wire 2 months ago
ImmunityBio, Inc. (NASDAQ:IBRX): When Will It Breakeven?

ImmunityBio, Inc. (NASDAQ:IBRX): When Will It Breakeven?
Simply Wall St. 2 months ago
ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG

ImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCG
Business Wire 2 months ago
ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million

ImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 Million
Business Wire 3 months ago
ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference

ImmunityBio to Participate in 35th Annual Piper Sandler Healthcare Conference
Business Wire 5 months ago
First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity

First Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor Activity
Business Wire 5 months ago
FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date

FDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA Date
Business Wire 5 months ago
View More

Related Tickers

MLEC Moolec Science SA
1.4500
+2.11%
 
BDRX Biodexa Pharmaceuticals Plc
1.3000
+80.56%
 
CDTX Cidara Therapeutics, Inc.
12.63
-2.85%
 
NKGN NKGen Biotech, Inc.
1.6100
-18.69%
 
IOVA Iovance Biotherapeutics, Inc.
11.64
+0.87%
 
VKTX Viking Therapeutics, Inc.
74.31
+7.91%
 
PCSA Processa Pharmaceuticals, Inc.
2.1500
-11.52%
 
PALI Palisade Bio, Inc.
6.05
-2.89%
 
ABEO Abeona Therapeutics Inc.
3.2600
+2.19%
 
DAWN Day One Biopharmaceuticals, Inc.
14.92
+12.94%